Inicia sesión Registrate Mi Biblioteca idioma

Idioma

biblioteca idioma abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará la selección de artículos sobre Trastornos del Movimiento clasificados según los 11 tipos establecidos por International Parkinson & Movement Disorder Society.

Enfermedad de Parkinson

2601 ARTíCULOS , VIENDO DEL 76 AL 90

PUBMED

From micrographia to Parkinson's disease dysgraphia.

Letanneux A, Danna J, Velay JL, Viallet F, Pinto S.

Mov Disord. 2014 Oct;29(12):1467-75. doi: 10.1002/mds.25990. Review.

0

0

0

PUBMED

Nigral iron elevation is an invariable feature of Parkinson's disease and is a sufficient cause of neurodegeneration.

Ayton S, Lei P.

Biomed Res Int. 2014;2014:581256. doi: 10.1155/2014/581256. Review.

0

0

0

PUBMED

Pull test performance and correlation with falls risk in Parkinson's disease.

Munhoz RP, Teive HA.

Arq Neuropsiquiatr. 2014 Aug;72(8):587-91.

0

0

0

PUBMED

MTHFR C677T variant reduces risk of sporadic Parkinson's disease in ethnic Chinese.

Liao Q, Li NN, Mao XY, Chang XL, Zhao DM, Zhang JH, Yu WJ, Tan EK, Peng R.

Acta Neurol Scand. 2014 Jul;130(1):e30-4. doi: 10.1111/ane.12245.

0

0

0

PUBMED

Comorbidity and functional mobility in persons with Parkinson disease.

King LA, Priest KC, Nutt J, Chen Y, Chen Z, Melnick M, Horak F.

Arch Phys Med Rehabil. 2014 Nov;95(11):2152-7. doi: 10.1016/j.apmr.2014.07.396.

0

0

0

PUBMED

Interventions that improve body and brain bioenergetics for Parkinson's disease risk reduction and therapy.

Mattson MP.

J Parkinsons Dis. 2014;4(1):1-13. doi: 10.3233/JPD-130335. Review.

0

0

0

PUBMED

Prospective memory performance of patients with Parkinson's disease depends on shifting aptitude: evidence from cognitive rehabilitation.

Costa A, Peppe A, Serafini F, Zabberoni S, Barban F, Caltagirone C, Carlesimo GA.

J Int Neuropsychol Soc. 2014 Aug;20(7):717-26. doi: 10.1017/S1355617714000563.

0

0

0

PUBMED

A conditioned response as a measure of impulsive-compulsive behaviours in Parkinson's disease.

Evans AH, Kettlewell J, McGregor S, Kotschet K, Griffiths RI, Horne M.

PLoS One. 2014 Feb 24;9(2):e89319. doi: 10.1371/journal.pone.0089319.

0

0

0

PUBMED

Impulse control and repetitive behaviors in Parkinson's disease - are there differences in the relation to dopamine agonist treatment?

Somme JH, Gómez-Esteban JC, Tijero B, Berganzo K, Lezcano E, Zarranz JJ.

J Neurol Sci. 2014 Oct 15;345(1-2):252-3. doi: 10.1016/j.jns.2014.07.004. No abstract available.

0

0

0

PUBMED

n-butylidenephthalide protects against dopaminergic neuron degeneration and α-synuclein accumulation in Caenorhabditis elegans models of Parkinson's disease.

Fu RH, Harn HJ, Liu SP, Chen CS, Chang WL, Chen YM, Huang JE, Li RJ, Tsai SY, Hung HS, Shyu WC, Lin SZ, Wang YC.

PLoS One. 2014 Jan 8;9(1):e85305. doi: 10.1371/journal.pone.0085305.

0

0

0

PUBMED

ERKed by LRRK2: a cell biological perspective on hereditary and sporadic Parkinson's disease.

Verma M, Steer EK, Chu CT.

Biochim Biophys Acta. 2014 Aug;1842(8):1273-81. doi: 10.1016/j.bbadis.2013.11.005. Review.

0

0

0

PUBMED

Targeting GTPases in Parkinson's disease: comparison to the historic path of kinase drug discovery and perspectives.

Hong L, Sklar LA.

Front Mol Neurosci. 2014 Jun 5;7:52. doi: 10.3389/fnmol.2014.00052. Review.

0

0

0

PUBMED

Exenatide as a potential treatment for patients with Parkinson's disease: first steps into the clinic.

Foltynie T, Aviles-Olmos I.

Alzheimers Dement. 2014 Feb;10(1 Suppl):S38-46. doi: 10.1016/j.jalz.2013.12.005. Review.

0

0

0

PUBMED

Uneven age effects of [(18)F]FP-CIT binding in the striatum of Parkinson's disease.

Lee CS, Kim SJ, Oh SJ, Kim HO, Yun SC, Doudet D, Kim JS.

Ann Nucl Med. 2014 Nov;28(9):874-9. doi: 10.1007/s12149-014-0882-1.

0

0

0

PUBMED

α-Synuclein and mitochondrial bioenergetics regulate tetrahydrobiopterin levels in a human dopaminergic model of Parkinson disease.

Ryan BJ, Lourenço-Venda LL, Crabtree MJ, Hale AB, Channon KM, Wade-Martins R.

Free Radic Biol Med. 2014 Feb;67:58-68. doi: 10.1016/j.freeradbiomed.2013.10.008.

0

0

0

Comentarios

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo HONcode Logo WIS

En colaboración con:

Zambon Neuroacademy